VRNA Verona Pharma plc

Verona Pharma plc

Biotechnology: Pharmaceutical Preparations

Health Care

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. It also focuses on developing ensifentrine for the treatment of COVID-19. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.

IPO Year: 2017

Exchange: NASDAQ

Website: veronapharma.com

Peers

$KALV

$MTP

Recent Analyst Ratings for Verona Pharma plc

Date	Price Target	Rating	Analyst
4/28/2025	$100.00	Buy	TD Cowen
4/21/2025	$80.00	Overweight	Cantor Fitzgerald
1/10/2025	$68.00	Buy	ROTH MKM
10/3/2024	$50.00	Overweight	Wells Fargo
5/22/2023	$35.00 → $38.00	Buy	Jefferies
9/19/2022	$27.00	Outperform	Wedbush
8/26/2022	$31.00	Overweight	Piper Sandler
11/12/2021	$18.00 → $23.00	Buy	Canaccord Genuity
9/13/2021	$25.00	Buy	HC Wainwright & Co.

See more ratings

Verona Pharma plc

Peers

Recent Analyst Ratings for Verona Pharma plc

Verona Pharma plc Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Ebsworth David R bought $88,800 worth of Ordinary Shares (20,000 units at $4.44), increasing direct ownership by 2% to 940,003 units (SEC Form 4)

Director Ebsworth David R bought $188,881 worth of Ordinary Shares (39,360 units at $4.80), increasing direct ownership by 4% to 920,003 units (SEC Form 4)

Director Ackermann Christina bought $198,386 worth of Ordinary Shares (41,880 units at $4.74) (SEC Form 4)

Director Ebsworth David R bought $103,320 worth of Ordinary Shares (36,000 units at $2.87), increasing direct ownership by 4% to 880,643 units (SEC Form 4)

Edwards Martin bought $61,973 worth of Ordinary Shares (33,736 units at $1.84), increasing direct ownership by 30% to 144,800 units (SEC Form 4)

Ebsworth David R bought $316,080 worth of Ordinary Shares (160,000 units at $1.98), increasing direct ownership by 23% to 844,643 units (SEC Form 4)

Verona Pharma plc SEC Filings

SEC Form 144 filed by Verona Pharma plc

SEC Form 144 filed by Verona Pharma plc

SEC Form 144 filed by Verona Pharma plc

SEC Form 144 filed by Verona Pharma plc

SEC Form 144 filed by Verona Pharma plc

Amendment: SEC Form SCHEDULE 13G/A filed by Verona Pharma plc

SEC Form SCHEDULE 13G filed by Verona Pharma plc

SEC Form 144 filed by Verona Pharma plc

SEC Form 144 filed by Verona Pharma plc

SEC Form 144 filed by Verona Pharma plc